The Trump administration has ceased funding for research involving aborted fetal tissue, as confirmed by a spokesperson from the Department of Health and Human Services (HHS). This policy, effective immediately, means that the National Institutes of Health (NIH) will no longer allocate funds for such research. Interestingly, this announcement arrived just a day before the March for Life event.
In discussing the policy shift, the NIH stated this was a significant step in the administration’s efforts to modernize biomedicine and foster innovation. NIH Director Jay Bhattacharyya mentioned, “NIH is moving American biomedicine into the 21st century.” He emphasized that this decision aims to further scientific advancements by investing in innovative technologies that can better replicate human health and diseases. Under President Trump’s leadership, he stressed the importance of ensuring that taxpayer-funded research aligns with the best contemporary science and reflects the values of the American population.
Since 2019, NIH-supported research utilizing fetal tissue has been on a decline, with just 77 projects funded in fiscal year 2024. The agency pointed out that advancements like organoids, tissue chips, and computational biology could contribute to scientific research while addressing ethical dilemmas.
The March for Life is an annual gathering that rallies pro-life advocates in Washington, DC, coinciding with the anniversary of the Supreme Court’s 1973 Roe v. Wade ruling—overturned in 2022.
This year, Vice President J.D. Vance is set to speak at the event again, just as he did last year. Recently, he and his wife Usha shared the news of expecting their fourth child. The White House congratulated the vice president and his family, calling the Trump administration “the most pro-family administration in history.” Alongside Vance, House Speaker Mike Johnson and Representative Chris Smith are also scheduled to address the audience during the rally.
